Chimeric antigen receptor specific to cd117
AssigneeCrispr Therapeutics AG
InventorsJason SAGERT, Peter HALLOCK
Life of this patent
Estimating the term…
Abstract
A chimeric antigen receptor (CAR) that binds CD117 (anti-CD117 CAR), wherein the anti-CD117 CAR comprises: (a) an ectodomain that binds CD 117; (b) a transmembrane domain; and (c) an endodomain comprising a costimulatory domain and a CD3ζ signaling domain. The ectodomain comprises a single chain variable fragment (scFv) that binds CD 117 (anti-CD117 scFv), or comprises a single domain antibody fragment such as a VHH fragment. Also provided herein are genetically engineered T cells expressing such anti-CD117 CAR, which can be used for inhibiting CD117+ cells such as cancer cells.
Claims32
A chimeric antigen receptor (CAR) that binds CD117 (anti-CD117 CAR), wherein the anti-CD117 CAR comprises:
- (a) an ectodomain that binds CD117;
- (b) a transmembrane domain;
- and
- (c) an endodomain comprising a costimulatory domain and a CD3ζ signaling domain;
- wherein the ectodomain comprises comprising a single chain variable fragment (scFv) that binds CD117 (anti-CD117 scFv), which comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising the same heavy chain complementarity determining regions (CDRs) and the same light chain CDRs as those in Reference anti-CD117 antibody 1 or Reference anti-CD117 antibody 2;
- or
- wherein the ectodomain comprises a single domain antibody fragment comprising:
- (i) a CDR1 set forth as GX1X2TX3X4X5X6X7, in which X1 is T, R, G, H, or D;
- X2 is T or absent;
- X3 is F, L, S, or V;
- X4 is G, S, or T;
- X5 is I, N, S, T or Y;
- X6 is D, V, or Y;
- and X7 is A, F, P, S, V or W;
- (ii) CDR2 set forth as X8X9X10X11X12X13X14X15, in which X8 is I or V;
- X9 is A, G, H, L, R, S, T, or V, X10 is R, S, or W;
- X11 is G, N, S, or Y;
- X12 is A, G, L, or absent;
- X13 is A, D, G, L, or S;
- X14 is G, M, S, T, or V;
- and X15 is A, L, or T;
- and
- (iii) CDR3 set forth as:
- (a)
- (SEQ ID NO:
- 70)
- GRFHPIRVDTA;
- (b)
- (SEQ ID NO:
- 71)
- ASGSNWRLGAIDEY;
- (c)
- (SEQ ID NO:
- 72)
- GQHLSGLGGSAWSIEG;
- (d)
- (SEQ ID NO:
- 73)
- RQYVGSGSYYLKKEGGY;
- (e)
- (SEQ ID NO:
- 74)
- DSTGVYGTGYVSSRKGRY;
- (f)
- (SEQ ID NO:
- 75)
- AFTPEFRDGGIWDDASV;
- (g)
- (SEQ ID NO:
- 78)
- VRRRWLIWQEEEY;
- (h)
- (SEQ ID NO:
- 80)
- DQRGVPAYYSDYALY;
- (i)
- (SEQ ID NO:
- 81)
- DESFPAYYSDYALY;
- (j)
- (SEQ ID NO:
- 69)
- VLRTGM;
- (k)
- (SEQ ID NO:
- 76)
- SDSYFYASPHLY;
- (l)
- (SEQ ID NO:
- 77)
- SDTYFYASPHLY;
- or
- (m)
- (SEQ ID NO:
- 79)
- RRGTILVVQEYEY.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-36. (canceled)
-52. (canceled)
Dependencies are inferred from the claim text.